The influence of six cardiovascular polymorphisms on a first event of ischemic heart disease is modified by sex and age

Coronary Artery Disease

Volumn 20, Issue 8, 2009, Pages 499-505

  Plat, Arian W ^a,b   Stoffers, Henri E ^a   De Leeuw, Peter W ^b   Van Schayck, Constant P ^a   Soomers, Frank L ^a   Kester, Arnold D ^b   Aretz, Karin ^a   Kroon, Abraham A ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age; Genetics; Ischemic heart disease; Rennin angiotensin system; Sex; Single nucleotide polymorphism

Indexed keywords

ALPHA ADDUCIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; FEMALE; GENOTYPE; GROUPS BY AGE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; AGED; ANGIOTENSINOGEN; CALMODULIN-BINDING PROTEINS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NITRIC OXIDE SYNTHASE TYPE III; ODDS RATIO; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PRIMARY HEALTH CARE; RECEPTOR, ANGIOTENSIN, TYPE 1; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 74249122725     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328330d541     Document Type: Article

References (43)

1. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin -angiotensin system. Circulation 1993; 87:1816-1828.
2. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol 2001; 87:25C-32C.
3. Ferrario CM, Richmond RS, Smith R, Levy P, Strawn WB, Kivlighn S. Renin-angiotensin system as a therapeutic target in managing atherosclerosis. Am J Ther 2004; 11:44-53.
4. Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens Suppl 1994; 12:S3-S10.
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153. (Pubitemid 30051645)
6. Carluccio M, Soccio M, De Caterina R. Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system. Eur J Clin Invest 2001; 31:476-488.
7. Visvikis-Siest S, Marteau JB. Genetic variants predisposing to cardiovascular disease. Curr Opin Lipidol 2006; 17:139-151.
8. Hegele RA. SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol 2002; 22:1058-1061.
9. Vineis P, McMichael AJ. Bias and confounding in molecular epidemiological studies: special considerations. Carcinogenesis 1998; 19:2063-2067.
10. Campbell H, Rudan I. Interpretation of genetic association studies in complex disease. Pharmacogenomics J 2002; 2:349-360.
11. Henskens LH, Spiering W, Stoffers HE, Soomers FL, Vlietinck RF, de Leeuw PW, et al. Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: first results of the Hippocrates study. J Hypertens 2003; 21:81-86.
12. Van Onna M, Kroon AA, Houben AJ, Koster D, Zeegers MP, Henskens LH, et al. Genetic risk of atherosclerotic renal artery disease: the candidate gene approach in a renal angiography cohort. Hypertension 2004; 44:448-453.
13. Plat AW, te Wierik MJ, Kroon AA, Schouten HJ, van den Akker M, van Schayck CP, et al. Regional differences in cardiovascular risk factor profile cannot fully explain differences in cardiovascular morbidity in the Netherlands: a comparison of two urban areas. Neth J Med 2005; 63:309-315.
14. Metsemakers JF, Knottnerus JA, van Schendel GJ, Kocken RJ, Limonard CB. Unlocking patients' records in general practice for research, medical education and quality assurance: the Registration Network Family Practices. Int J Biomed Comput 1996; 42:43-50.
15. Landwehr JSTM, Akker Mvd, Metsemakers JFM, Buntinx F. Comorbidity of chronic cardiovascular disorders. A cross-sectional analysis in a large general practice population in the Netherlands. Archiv Public Health 2000; 58:213-231. (Pubitemid 32798829)
16. Classification Committee of Wonca. Oxford: Oxford University Press; 1983.
17. Lamberts H, Wood M. ICPC: International Classification of Primary Care. Oxford: Oxford University Press; 1987.
18. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21:1779-1786.
19. Knaapen AM, Ketelslegers HB, Gottschalk RW, Janssen RG, Paulussen AD, Smeets HJ, et al. Simultaneous genotyping of nine polymorphisms in xenobiotic-metabolizing enzymes by multiplex PCR amplification and single base extension. Clin Chem 2004; 50:1664-1668.
20. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996; 58:1268-1278.
21. Keavney B, McKenzie CA, Connell JM, Julier C, Ratcliffe PJ, Sobel E, et al. Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet 1998; 7:1745-1751.
22. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002; 20:2023-2027.
23. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: J Wiley; 2000.
24. O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, et al. Evidence for association and genetic linkage of the angiotensin- converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998; 97:1766-1772.
25. Higaki J, Baba S, Katsuya T, Sato N, Ishikawa K, Mannami T, et al. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita study. Circulation 2000; 101:2060-2065.
26. Wang JG, Staessen JA, Barlassina C, Fagard R, Kuznetsova T, Struijker-Boudier HA, et al. Association between hypertension and variation in the alpha- and beta-adducin genes in a White population. Kidney Int 2002; 62:2152-2159.
27. Brand E,Wang JG, Herrmann SM, Staessen JA. An epidemiological study of blood pressure and metabolic phenotypes in relation to the Gbeta3 C825 T polymorphism. J Hypertens 2003; 21:729-737.
28. Shin J, Lobmeyer MT, Gong Y, Zineh I, Langaee TY, Yarandi H, et al. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 2007; 99: 250-255.
29. Hingorani A. Resolving inconsistency in the results of genetic association studies of cardiovascular disease. Clin Sci (Lond) 2004; 107:251-253.
30. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001; 37:1199-1208.
31. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
32. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111:383-390.
33. Goldberg RJ, O'Donnell C, Yarzebski J, Bigelow C, Savageau J, Gore JM. Sex differences in symptom presentation associated with acute myocardial infarction: a population-based perspective. Am Heart J 1998; 136:189-195.
34. Province MA, Arnett DK, Hunt SC, Leiendecker-Foster C, Eckfeldt JH, Oberman A, et al. Association between the alpha-adducin gene and hypertension in the HyperGEN Study. Am J Hypertens 2000; 13:710-718.
35. Castellano M. Genetic association studies on gender-related and age-related phenotypes: the case of GNB3 gene. J Hypertens 2003; 21:683-685.
36. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2003; 23:1269-1275.
37. Sekuri C, Cam FS, Ercan E, Tengiz I, Sagcan A, Eser E, et al. Reninangiotensin system gene polymorphisms and premature coronary heart disease. J Renin Angiotensin Aldosterone Syst 2005; 6:38-42.
38. Fernandez-Arcas N, Dieguez-Lucena JL, Munoz-Moran E, Ruiz-Galdon M, Espinosa-Caliani S, Aranda-Lara P, et al. Both alleles of the M235 T polymorphism of the angiotensinogen gene can be a risk factor for myocardial infarction. Clin Genet 2001; 60:52-57.
39. Schunkert H, Hense HW, Doring A, Riegger GA, Siffert W. Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998; 32:510-513.
40. Zeltner R, Delles C, Schneider M, Siffert W, Schmieder RE. G-protein beta(3) subunit gene (GNB3) 825 T allele is associated with enhanced renal perfusion in early hypertension. Hypertension 2001; 37:882-886.
41. Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med 2005; 56:17-28.
42. Lizanecz E, Pasztor ET, Mohacsi A, Papp Z, Edes I, Toth A. Mistyping of angiotensinogen M235 T alleles. Hypertens Res 2006; 29:197-201.
43. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361:567-571.